Navigation Links
Research provides insight into new drug resistance in hospital microbes
Date:7/13/2011

Boston (July 13, 2011) Hospitals struggle to prevent the infections that complicate treatment for cancer, joint replacement, heart surgery and other conditions. Hospital-acquired infections are often resistant to multiple antibiotics, leading to approximately 100,000 deaths and more than $30 billion in additional health care costs yearly. New drugs are being developed to combat these infections, but resistance invariably emerges to these last-line drugs.

Daptomycin, a new antibiotic approved by the FDA in 2003, is used to treat infections caused by multi-drug resistant bacteria, including staph and microbes known as enterococci. Scientists in the Department of Ophthalmology at Mass. Eye and Ear and Harvard Medical School, and the pharmaceutical company Cubist, which produces daptomycin under the trade name Cubicin, teamed up to discover the basis for resistance that has now begun to emerge to daptomycin in the enterococci. Their discovery of a new mechanism of resistance is described in an article in the current (July) issue of Antimicrobial Agents and Chemotherapy.

In a two-week experiment, investigators were able recreate the development of resistance in the laboratory in a manner similar to that which occurred in the hospital. Using new genome sequencing technology, they resequenced the entire genome of the resistant enterococcus strain to identify all of the genetic changes. The researchers found changes in genes that they were also able to identify in hospital daptomycin resistant strains. Mutations in a gene encoding an enzyme called cardiolipin synthase were able by itself to confer daptomycin resistance to a laboratory strain of enterococcus.

"Knowing the changes that correspond with resistance not only tells us what happens in resistant strains, it tells us much about how exactly how the antibiotic works, providing new ideas for better treatment and next generation drugs," observed Dr. Michael S. Gilmore, a scientist at Harvard Medical School and the Mass. Eye and Ear, and the corresponding author.


'/>"/>

Contact: Mary Leach
Mary_Leach@meei.harvard.edu
617-573-4170
Massachusetts Eye and Ear Infirmary
Source:Eurekalert

Related biology news :

1. TUM researchers discover a new switch in resistance to plant diseases
2. BUSM researchers urge awareness of dietary iodine intake in postpartum Korean-American women
3. Researchers study pesticide pathways into the atmosphere
4. Johns Hopkins researchers identify new genetic risk factor for sudden cardiac death
5. Renewal of agreement between Ipsen and the Salk Institute supports cutting-edge research
6. Johns Hopkins researchers awarded $32 million
7. BGI contributes whole genome sequencing and bioinformatics expertise to potato genome research
8. University of Kentucky-led research could be path to new energy sources
9. New research shows forest trees remember their roots
10. Research shows BPA-free bottles live up to manufacturers claims
11. AACR hosts Frontiers in Basic Cancer Research Conference in San Francisco
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... The biometrics market has reached a ... organizations, desires to better authenticate or identify users ... challenge questions), biometrics is quickly working its way ... is driven by use cases, though there traditionally ... uses cases, with consumer-facing use cases encompassing authentication, ...
(Date:2/6/2017)... Feb. 6, 2017 According to Acuity ... driving border authorities to continue to embrace biometric ... are 2143 Automated Border Control (ABC) eGates and ... at more than 163 ports of entry across ... 2016 achieving a combined CAGR of 37%. APC ...
(Date:2/2/2017)... 2017  Central to its deep commitment to ... The Japan Prize Foundation today announced the laureates ... the envelope in their respective fields of Life ... are being recognized with the 2017 Japan Prize ... contribute to the advancement of science and technology, ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... Feb. 23, 2017 /PRNewswire/ - The Fight Against Cancer ... Research (OICR) are pleased to report that Fusion Pharmaceuticals ... with Johnson & Johnson Innovation – JJDC, Inc. (JJDC) ... groups HealthCap, TPG Biotechnology Partners, and Genesys Capital, as ... ...
(Date:2/23/2017)... ... February 23, 2017 , ... Brain Sentinel, Inc. ... marketing the SPEAC® System, the Brain Sentinel® Seizure Monitoring and Alerting System. The ... facilities during periods of rest. A lightweight, non-invasive monitor is placed on the ...
(Date:2/23/2017)... Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing biological therapies ... Marbán, Ph.D, president and chief executive officer, is scheduled to ... Cowen and Company 37th Annual Health Care Conference Tuesday, March ... 29th Annual ROTH Conference Tuesday, ... Dana Point, CA ...
(Date:2/22/2017)... ANGELES, CA (PRWEB) , ... February 22, 2017 ... ... today announced that is has acquired Kendall Research Systems, LLC (KRS) ... Technology (MIT) that develops neural interface technology for research and clinical applications. The ...
Breaking Biology Technology: